Drug Profile
GSK 2831781
Alternative Names: GSK2831781; GSK‘781; ImmuTune-IMP731; IMP-731Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Immutep
- Developer GlaxoSmithKline; GSK
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action CD223 antigen modulators; Cytotoxic T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis
- Discontinued Ulcerative colitis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Plaque-psoriasis in United Kingdom (IV, Infusion)
- 28 Feb 2021 Clinical development for plaque psoriasis is still ongoing in Germany and United Kingdom (Immutep pipeline, March 2021)